Whether sponsors of new type 2 diabetes drugs must continue to exclude an unacceptable increase in cardiovascular (CV) risk is the lone voting question being put to the US FDA’s Endocrinologic and Metabolic Drugs Advisory Committee at an Oct. 24-25 meeting.
However, in deciding that question, FDA wants the panel be mindful of the CV and non-CV safety findings that have...





